The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

The family of a Yeadon boy diagnosed with cancer ten years ago is gearing up to host a sparkling ball to raise £10,000 for ...

A groundbreaking study has uncovered molecular markers in blood at birth that are linked to later development of acute ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

“With the U.S. Food and Drug Administration (FDA) having approved AUCATZYL ® (obe-cel) for the treatment of adult B-cell Acute Lymphoblastic Leukemia (B-ALL) patients, we are all systems go with our ...

IN A breakthrough study, researchers have reported encouraging outcomes using autologous chimeric antigen receptor (CAR) T ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Nearly 25 years ago, Ann and Jim Pride endured the unimaginable when their son Jeff — a happy boy who liked the color blue ...